Literature DB >> 16984370

Nucleophosmin: a versatile molecule associated with hematological malignancies.

Tomoki Naoe1, Tatsuya Suzuki, Hitoshi Kiyoi, Takeshi Urano.   

Abstract

Nucleophosmin (NPM) is a nucleolar phosphoprotein that plays multiple roles in ribosome assembly and transport, cytoplasmic-nuclear trafficking, centrosome duplication and regulation of p53. In hematological malignancies, the NPM1 gene is frequently involved in chromosomal translocation, mutation and deletion. The NPM1 gene on 5q35 is translocated with the anaplastic lymphoma kinase (ALK) gene in anaplastic large cell lymphoma with t(2;5). The MLF1 and RARA genes are fused with NPM1 in myelodysplastic syndrome and acute myeloid leukemia (AML) with t(3;5) and acute promyelocytic leukemia with t(5;17), respectively. In each fused protein, the N-terminal NPM portion is associated with oligomerization of a partner protein leading to altered signal transduction or transcription. Recently, mutations of exon 12 have been found in a significant proportion of de novo AML, especially in those with a normal karyotype. Mutant NPM is localized aberrantly in the cytoplasm, but the molecular mechanisms for leukemia remain to be studied. Studies of knock-out mice have revealed new aspects regarding NPM1 as a tumor-suppressor gene. This review focuses on the clinical significance of the NPM1 gene in hematological malignancies and newly discovered roles of NPM associated with oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984370     DOI: 10.1111/j.1349-7006.2006.00270.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  27 in total

Review 1.  Ribosomopathies: human disorders of ribosome dysfunction.

Authors:  Anupama Narla; Benjamin L Ebert
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

2.  Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.

Authors:  Rolf K Swoboda; Rajasekharan Somasundaram; Laura Caputo; Klara Berencsi; Paul von Franzke; Douglas D Taylor; Francesco M Marincola; Neal J Meropol; Elin Sigurdson; Eric Miller; Dorothee Herlyn
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

3.  p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.

Authors:  Sriram Venneti; Paul Le; Daniel Martinez; Katherine W Eaton; Nikhil Shyam; Kelly L Jordan-Sciutto; Bruce Pawel; Jaclyn A Biegel; Alexander R Judkins
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

4.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Authors:  Ramesh Balusu; Warren Fiskus; Rekha Rao; Daniel G Chong; Srilatha Nalluri; Uma Mudunuru; Hongwei Ma; Lei Chen; Sreedhar Venkannagari; Kyungsoo Ha; Sunil Abhyankar; Casey Williams; Joseph McGuirk; Hanna Jean Khoury; Celalettin Ustun; Kapil N Bhalla
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

5.  Fine-tuning nucleophosmin in macrophage differentiation and activation.

Authors:  Leslie Guery; Naïma Benikhlef; Thomas Gautier; Catherine Paul; Gaetan Jego; Erick Dufour; Arnaud Jacquel; Radj Cally; Bénédicte Manoury; Tom Vanden Berghe; Peter Vandenabeele; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2011-08-29       Impact factor: 22.113

6.  The natural product avrainvillamide binds to the oncoprotein nucleophosmin.

Authors:  Jeremy E Wulff; Romain Siegrist; Andrew G Myers
Journal:  J Am Chem Soc       Date:  2007-10-25       Impact factor: 15.419

7.  NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling.

Authors:  Mikael S Lindström
Journal:  Biochem Res Int       Date:  2010-10-05

8.  Nucleophosmin is a binding partner of nucleostemin in human osteosarcoma cells.

Authors:  Hanhui Ma; Thoru Pederson
Journal:  Mol Biol Cell       Date:  2008-04-30       Impact factor: 4.138

9.  Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation.

Authors:  Zhaoliang Li; David Boone; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

10.  Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes.

Authors:  Tal Shay; Wanyu L Lambiv; Anat Reiner-Benaim; Monika E Hegi; Eytan Domany
Journal:  Cancer Inform       Date:  2009-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.